For instance, MRX34 was the first miRNA-based therapy undergoing in a clinical trial for cancer treatment, its aim was to re-express miR-34, that regulates LDHA, by introducing a mimic sequence through the lipid carrier NOV40 to treat patients with lymphoma, melanoma, multiple myeloma, liver, small cell lung, and renal carcinoma. This evidence concerns the gene LDHA and cancer.